Drug Discovery Instruments, Hamamatsu

	Login	.	Language

System Division

Bio Imaging Instruments

Non-Destructive Testing / X-ray

Semiconductor Industry

Laser & Fiber Optic Measurement

Body Line Scanner

Medical Instruments

Drug Discovery Instruments / FDSS

Features & Benefits

Application Notes

Request Info

Virtual Microscopy / NanoZoomer

Posters

Click the Image to View	Citation
	Chromovert® Produces Clones Stably and Functionally Expressing a Multigene Ion Channel Author: Jessica Langer, Alane Taratuska, Purvi Shah, Lori Schmid and Kambiz Shekdar Chromocell Corporation, 675 U.S. Highway One, North Brunswick, NJ Source: Venue: Society for Biomolecular Screening, Geneva Switzerland Date: November 2005
	Cell Plate Mixing versus Pipet Mixing, A Comparative Study on Reducing DMSO Artifacts and Improving Assay Performance Using the FDSS6000 Author: K. Cassutt¹, S. Du¹, M. Abbouslelmin², W. Tang² Hamamatsu Corpation, Bridgwater, NJ PRDUS, Raritan, NJ Source: Society for Biomolecular Screening, Geneva Switzerland Date: September 2005
	Membrane Potential Assay to Identify Ion Channel Modulators Author: Presented by: Shephali Trivedi¹, Ronald Julien¹, Kelly Cassutt², Jian Huang¹, Kim Dekermendjian¹, Per-Eric Lund¹, Johannes Krupp¹ and Robert Bostwick¹ Lead Generation, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850 Hamamatsu Corporation, Bridgewater,NJ Source: Society for Biomolecular Screening Date: November 2005
	Multiplexing Cell Based Assays in HTS Author: K. Cassutt, Al McGrath, Masanobu Fujiwara and Shouming Du, Hamamatsu Photonics Corporation Source: World Pharmaceutical Congress, Philadelphia, PA Date: November 2005 Abstract: The FDSS6000 from Hamamatsu uses Xenon lamps, enabling the use of fluorescent dyes ranging from UV to visible excitation wavelengths. The FDSS6000 can record up to two excitation wavelengths and two emission wavelengths in the same assay. Current screening strategies use only one dye per assay, such as Fura-2AM, Fluo-3AM, or Fluo-4AM (calcium mobilization), or DisBAC2(3) (membrane potential). We present a novel multiplexing method for HTS Screening: Loading the same cells using both the UV dye Fura-2AM and a no wash Membrane Potential Dye. Multiplexing assays measure orthogonal cell responses (calcium mobilization and membrane potential) using one volume of valuable library compound.
	Can Aequorin technology reduce false positives in GPCR primary screening? Author: W. Tang¹, K. Cassutt², M. Abbouslelmin¹, D. Colone¹, S. Du², and Mary Jo Wildey¹ Source: Society for Biomolecular Screening, Geneva Switzerland Date: November 2004
	Data Analysis Algorithm Choice Affects Both Z' Factor and Hit Detection: A Case Study Using FDSS6000 Author: K. Cassutt¹, S. Du¹, M. Abbouslelmin², W. Tang², and C. Allee³ Source: Society for Biomolecular Screening, Geneva Switzerland Date: November 2004
	Multiplexing Nonadherent Cells Loaded Using One of Two Calcium Indicator Dyes: Effect on Calcium Mobilization Detection and Analysis Using the FDSS6000 Author: M. Fujiwara¹, A. McGrath¹, S. Du¹, K. Cassutt¹, D. Colone², M. Abbouslelmin², and W. Tang² Source: Society for Biomolecular Screening, Geneva Switzerland Date: November 2004
	A dual dye method for reducing false positives and rescuing compounds of interest in fluorescent calcium assays Author: Christopher M. Fanger and Xiaoguang Zhen Source: Society for Biomolecular Screening, Geneva Switzerland Date: November 2004
	A Semi-Automated Approach for High Throughput Screening using HamamatsuPhotonics FDSS6000 Author: BabuPS, UbertiM, RanaganathanA, MenonV, Bhatia S, Ramirez FE, PropheteR, EldemenkyE, ZhengY, Dong H and Jones KA High Throughput Screening, of Cellular Sciences, Lundbeck Research USA, Paramus, NJ 07652 Source: Society for Biomolecular Screening, Geneva Switzerland Date: November 2004 Abstract: We describe a semi-automated approach to screen 350,000 compound collection using the HamamatsuPhotonics FDSS6000. The system consisted of a FDSS 6000, a Bio-Tek384-well plate washer and a Matrix platemate2 X 2. In brief, cells in 384-well plates were washed and loadedwith Fluo-4 in batches of ten for a 60 min incubation. After incubation,cells were washed and compounds were added 30 min prior to agonist addition. Compound addition and agonist addition were recorded for 3 min on the FDSS 6000. Availability of historical binding data on 4700 compounds, included in the HTS, allowed us to demonstrate an excellent correlation in identifying hits between the two assay platforms.For the entire screen, we have calculated Z-prime values above 0.7, which demonstrates a robust and highly reproducible functional assay. We completed the screen in six weeks and concluded that this approach is suitable for conventional functional HTS.
	Development of FDSS6000-based High-Throughput Screening (HTS) Assay for T-type Ca²⁺ Channels Author: Yoonji Kim, Sonhe So, Dongjin Kim and Hyewhon Rhim of the Biomedical Research Center, Kora Institute of Science & Technology (KIST) Seoul, Korea Source: Society for Biomolecular Screening, Geneva Switzerland Date: November 2004 Abstract: Voltage-dependent Ca²⁺ channels have diverse functions, including crucial roles in excitability, neurotransmission, intracellular signaling pathways, and gene expression. Among them, T-type Ca²⁺ channels have been implicated in pathogenesis of epilepsy and neuropathic pain. However, limited progress has been made to develop potent and selective T-type Ca²⁺ channel blockers. We, therefore, constructed a cell line in which high concentration of KCl can activate Ttype Ca²⁺ channels. Treatment of 70 mM KCl in this cell line increased [Ca²⁺]i, which was blocked by mibefradil. Furthermore, we set-up a HTS assay for T-type Ca²⁺ channels using Hamamatsu FDSS6000. When the increase in [Ca²⁺]i via an activation of T-type Ca²⁺ channels was measured using the fluorescent Ca²⁺ indicator, Fluo-3, IC50 values of Ni²⁺ and mibefradil were 162.6 ± 65.9 and 6.7 ± 0.9 µM, respectively, which were close to the reported values. These results offer a potential HTS approach to discover new therapeutic drugs associated with T-type Ca²⁺ channels.
	Effect of Assay Design and Data Analsysis on Apparent pIC₅₀ and pA₂ Using a Rationmetric Cell Based Calcum Mobilization Assay on the Functional Drug Screening System (FDSS 6000) Author: S. Du, K.Cassutt, M. Fujuwara, and A. McGrath of Hamamatsu Photonics Corporation Source: World Pharmaceutical Congress, Philadelphia, PA Date: November 2004
	Effect of Assay Design and Data Analsysis on Apparent pIC₅₀ and pA₂ Using a Cell-Based Calcum Mobilization Assay on the Functional Drug Screening System (FDSS 6000) Author: S. Du, K.Cassutt, M. Fujuwara, and A. McGrath of Hamamatsu Corporation Source: SBS Regional Meeting: Exploiting the Druggabl Genome: A West Coast Focus, San Mateo, CA Date: November 2004 Abstract: The transient nature of the G protein-coupled receptor mediated calcium mobilization cycle severely limits measuring antagonist potency at agonist/antagonist/receptor equilibrium. As a consequence assay design and data analysis can affect apparent antagonist potency, both pIC50 and pA2 1. With pre-incubation the antagonist-receptor offrate influences potency; by contrast with agonist/antagonist co-administration the antagonist-receptor on-rate influences potency. Assays with both modalities may offer a more complete picture of the agonist/antagonist/receptor interaction in vitro resulting in improved in vivo predictions of antagonist potency. In the present study we demonstrate using the FDSS60001) Fluo-4 AM concentration affects the kinetic response to agonist and2) assay design and data analysis affects apparent pIC50 and pA2.

© Hamamatsu Corporation. Customer privacy is important, please read our privacy statement. Please send comments/questions about this page to the Webmaster.